The advent of the third generation of cytotoxic agents led to some improvements in survival of patients affected by advanced NSCLC; however, the prognosis for these patients is still dire, the choice of an optimal treatment strategy remains challenging, and relevant biomarkers are needed, especially when targetable oncogenic drivers, such as EGFR or ALK, are missing. This evidence concerns the gene ALK and non-small cell lung carcinoma.